KEYNOTE-B49

1. 03:22
   x.com

   #ScienceLink #Madrid2026 #ESMO26 #KEYNOTEB49 #CancerDeMama

1. 22:36
   x.com

   STATISTICALLY POSITIVE. CLINICALLY THIN.
2. 19:18
   mp.weixin.qq.com
3. 16:52
   x.com

   #ESMO26 @myESMO #ESMOAmbassords new data from Keynote-b49 👇🏼
4. 15:47
   x.com

   KEYNOTE-B49 at #ESMO26
5. 15:18
   x.com

   🔥 KEYNOTE-B49 meets its primary endpoint, but benefit seems limited to few patients
6. 15:16
   x.com

   PD-(L)1 blockade has made inroads into triple-negative breast cancer, but ER+/Her2- space is still a no go, judging by $MRK flop in Keynote-B49. From #Esmo26 via @ApexOnco -> ht
7. 15:15
   x.com

   Another reminder that immunotherapy is not a universal solution.
8. 15:05
   x.com

   After so much effort to bring immunotherapy into HR+/HER2− mBC, KEYNOTE-B49 raises a hard question: is this worth it? A 0.7-month median PFS gain and no demonstrated OS benefit. We
9. 14:57
   x.com

   KEYNOTE-B49 highlights an important distinction:
10. 14:54
    x.com

    KEYNOTE-B49 presented by @hoperugo at #ESMO26
11. 14:52
    x.com

    For my breast oncology colleagues:
12. 14:52
    x.com

    One question I would ask the KEYNOTE-B49 investigators:
13. 14:51
    x.com

    KEYNOTE-B49 raises a familiar oncology dilemma:
14. 14:49
    x.com

    📌 Proffered paper 2: Breast cancer, early and advanced stage
15. 14:48
    x.com

    Could PD-L1 selection be the real story in KEYNOTE-B49?
16. 14:48
    x.com

    An important question for KEYNOTE-B49 at #ESMO26:
17. 14:45
    x.com

    #ESMO26 | KEYNOTE-B49 – Phase III
18. 14:44
    x.com

    KEYNOTE-B49
19. 14:44
    x.com
20. 14:42
    x.com

    Where does KEYNOTE-B49 fit in today’s rapidly evolving breast cancer landscape?
21. 14:40
    x.com

    KEYNOTE-B49 at #ESMO26 raises a fundamental question:
22. 14:30
    x.com

    #ESMO26: Pembrolizumab plus chemotherapy reduced the risk of PFS by 26% in PD-L1-positive, HR-positive #AdvancedBreastCancer after failure on endocrine therapy in the phase III KEY
23. 14:30
    x.com

    📢 #ESMO26 concomitant paper - Pembrolizumab plus chemotherapy for HR+/HER2− PD-L1‒positive advanced breast cancer: final analysis of the phase 3 KEYNOTE-B49 Study.
24. 14:24
    x.com

    Starting with breast cancer at #ESMO26. KEYNOTE-B49 asks whether pembrolizumab + chemotherapy can improve outcomes in HR+/HER2− advanced disease. I’m particularly interested in PD-
25. 13:53
    x.com

    Live from #ESMO26 Madrid with @TargetedOnc!
26. 06:27
    x.com

    #ESMO26 | KEYNOTE-B49

1. 05:00
   x.com

   🚨6 breast cancer trials to watch at #ESMO26 from leading voices including @ErikaHamilton9 @HundalJasmin and Nusrat Jahan, MD 🔗https://www.cancernetwork.com/view/from-keynote-b49-to

Heat now 99·Peak in the comparable set 136 (Oct 24 17:00)·Change over 24h in the comparable set +2324%·Participants now 18

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.